Preparing for WNV Season and Donor Testing: AABB Reminds Blood Collection Facilities to Report Reactive Donations to Its WNV Network to Support Transfusion Safety

August 25, 2021

AABB’s West Nile Virus (WNV) Biovigilance Network offers a unique platform for blood collection facilities to protect transfusion safety. This collaborative effort between AABB and blood collectors to report and track potential WNV-reactive donations enhances transfusion safety through the WNV Biovigilance Network communication necessary to implement the Food and Drug Administration’s recommendations for individual donor testing without delay. Patient safety improves when the blood collection community actively reports WNV testing, and AABB encourages blood collection facilities to support this transfusion safety effort by reporting both initial reactive donations and final test interpretations to the platform.

An increase in WNV-reactive donations has been reported to the network during the 2021 West Nile Virus season. Between June 1 - Aug. 24, blood collectors have reported 97 WNV-reactive donations, 31 of which were confirmed positive. The states reporting the highest number of confirmed-positive donations were Texas (7) and California (4). 

AABB members subscribed to the email alert list receive notification of all reported WNV activity to help trigger a transition from minipool to individual donor nucleic acid testing (ID NAT). Interested parties may contact hemovigilance@aabb.org to subscribe to the email alert. For more information, please visit the WNV Biovigilance web page.

The AABB Biovigilance Network supports and enhances an identification and tracking initiative of AABB, but it is not intended to supplant or replace public health agency data collection, or to predict the occurrence, frequency or location, but rather to support public health agencies, blood collection facilities and transfusion services.